| Description |
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].
|
| Related Catalog |
|
| In Vitro |
Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性，驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌[1]。
|
| In Vivo |
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退[1]。 Animal Model: Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1] Dosage: 0.25-0.3 mg/kg Administration: Intraperitoneal injection; twice a week, for 2 weeks Result: Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
|
| References |
[1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.
|
